Status:
COMPLETED
Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Psoriasis
Eligibility:
All Genders
18-100 years
Brief Summary
This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient charact...
Detailed Description
This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient charact...
Eligibility Criteria
Inclusion
- ≥1 orders/administrations for secukinumab within the index window (March 1, 2018 to August 31,2019 for the base analysis; March 1, 2018 to January 31, 2020 for the refresh analysis). The date of the first order or administration was be the index date
- Patients in the MMDS database with a diagnosis of PsO on or prior to the 1st secukinumab order/administration
- ≥18 years of age as of the index date
- To ensure capturing continuous patient activities in the EMR dataset, patients must have at least one more visit (any visit regardless of diagnosis) in addition to the index visit within the first 6 months after secukinumab initiation
- Patients must have at least one visit (any visit regardless of diagnosis) within the 12 months pre-index period
Exclusion
- Evidence of secukinumab use in the 12-month pre-index period
- Data quality issues (missing age, gender, prescription order information)
Key Trial Info
Start Date :
February 3 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2021
Estimated Enrollment :
17743 Patients enrolled
Trial Details
Trial ID
NCT05320159
Start Date
February 3 2021
End Date
March 31 2021
Last Update
July 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
East Hanover, New Jersey, United States, 07936-1080